Publications

Complete List of Published Works

https://orcid.org/0000-0002-8124-1265

*Corresponding author(s).

† These authors contributed equally to the article.

‡ These authors contributed equally to the article.

Bold texts indicate members of the Pishesha Lab.

2025

35. Growth inhibition of Saccharomyces cerevisiae by SUMO-specific nanobodies.

Suresh P*, Jim SZ, Sahay I, Tang AY, Wijne C, Gan J, Pishesha N, Avalos JL, Ploegh H*. Sci Rep. 2025 May 26;15(1):18368. doi: 10.1038/s41598-025-02380-6.

34. A nanobody that binds to the backside of the ubiquitin conjugating enzyme Ube2G2 differentially affects interactions with its partner E3 Ligases.

Suresh P*, Wijne C, Sun ZJ, Becht N, Sahay I, Pishesha N, Ploegh H. Commun Biol. 2025 Apr 16;8(1):614. doi: 10.1038/s42003-025-08038-3.

33. Nanobody-targeted conditional antimicrobial therapeutics.

Ngambenjawong C, Ko H, Samad T, Pishesha N, Ploegh HL, Bhatia SN*. ACS Nano. 2025 Mar 18;19(10):9958-9970. doi: 10.1021/acsnano.4c16007.

2024

32. Imaging the immune sequelae of infection with SARS-CoV-2 in nonhuman primates by using two nanobody PET-tracers.

Koopman G, Verhoeven T, Mooij P, Acar RF, Harmand T, Flanagan L, Bakker J, Böszörményi KP, Bontrop RE, Langermans JAM, Ploegh HL, Verschoor EJ, Vugts DJ, Pishesha N, Stammes MA*. J Med Virol. 2024 Oct;96(10):e29956. doi: 10.1002/jmv.29956.

31. MICA-specific nanobodies for diagnosis and immunotherapy of MICA+ tumors.

Verhaar ER, Knoflook A, Pishesha N, Liu X, van Keizerswaard WJC, Wucherpfennig KW, Ploegh HL*. Front Immunol. 2024 Mar 14;15:1368586. doi: 10.3389/fimmu.2024.1368586.

19. An in vivo selection-derived d-peptide for engineering erythrocyte-binding antigens that promote immune tolerance.

Loftis AR, Zhang G, Backlund C, Quartararo AJ, Pishesha N, Hanna CC, Schissel CK, Garafola D, Loas A, Collier RJ, Ploegh H, Irvine DJ, Pentelute BL. Proc Natl Acad Sci U S A. 2021 Aug 24;118(34):e2101596118. doi: 10.1073/pnas.2101596118.

31. Nanobody-targeted conditional antimicrobial therapeutics

Ngambenjawong C, Ko H, Pishesha N, Ploegh HL, Bhatia SN

doi: https://doi.org/10.1101/2024.02.20.580917

Harmand TJ, Islam A, Pishesha N, Ploegh HL. RSC Chem Biol. 2021 Mar 8;2(3):685-701. doi: 10.1039/d1cb00023c.

Pre-2024

30. A guide to antigen processing and presentation.

Pishesha N †, Harmand TJ †, Ploegh HL*†. Nat Rev Immunol. 2022 Dec;22(12):751-764. doi: 10.1038/s41577-022-00707-2.

29. An antibody from single human VH-rearranging mouse neutralizes all SARS-CoV-2 variants through BA.5 by inhibiting membrane fusion.

Luo S*†, Zhang J †, Kreutzberger AJB †, Eaton A, Edwards RJ, Jing C, Dai HQ, Sempowski GD, Cronin K, Parks R, Ye AY, Mansouri K, Barr M, Pishesha N, Williams AC, Vieira Francisco L, Saminathan A, Peng H, Batra H, Bellusci L, Khurana S, Alam SM, Montefiori DC, Saunders KO, Tian M, Ploegh H, Kirchhausen T*, Chen B*, Haynes BF*, Alt FW*. Sci Immunol. 2022 Oct 28;7(76):eadd5446. doi: 10.1126/sciimmunol.add5446.

28. Targeted delivery of an anti-inflammatory corticosteroid to Ly6C/G-positive cells abates severity of influenza A symptoms.

Pishesha N †, Harmand T †, Carpenet C †, Liu X †, Bhan A, Islam A, van den Doel R, Pinney W 3rd, Ploegh HL*. Proc Natl Acad Sci U S A. 2022 Oct 25;119(43):e2211065119. doi: 10.1073/pnas.2211065119.

27. Functional analyses and single cell immunoprofiling uncover sex-specific differences in SARS-CoV2 immune memory development.

Eraslan B, Brown E, Benson M, Amir-Zilberstein L, Park SM, Tusi B, Pokatayev V, Hecht C, Pishesha N, Phillips D, Kim A, Zhang S, Gaca A, Ghantous F, Delorey T, Livny J, Baden L, Rozenblatt-Rosen O, Graham D, Regev A, Seaman M, Woolley A, Cosimi L, Hung D, Deguine J, Xavier R*. Res Sq [Preprint]. 2022 Mar 15:rs.3.rs-1416969. doi: 10.21203/rs.3.rs-1416969/v1.

26. An adjuvant strategy enabled by modulation of the physical properties of microbial ligands expands antigen immunogenicity.

Borriello F, Poli V, Shrock E, Spreafico R, Liu X, Pishesha N, Carpenet C, Chou J, Di Gioia M, McGrath ME, Dillen CA, Barrett NA, Lacanfora L, Franco ME, Marongiu L, Iwakura Y, Pucci F, Kruppa MD, Ma Z, Lowman DW, Ensley HE, Nanishi E, Saito Y, O'Meara TR, Seo HS, Dhe-Paganon S, Dowling DJ, Frieman M, Elledge SJ, Levy O, Irvine DJ, Ploegh HL, Williams DL, Zanoni I*. Cell. 2022 Feb 17;185(4):614-629.e21. doi: 10.1016/j.cell.2022.01.009.

25. Noninvasive Immuno-PET Imaging of CD8+ T Cell Behavior in Influenza A Virus-Infected Mice.

Rothlauf PW †, Li Z †, Pishesha N, Xie YJ, Woodham AW, Bousbaine D, Kolifrath SC, Verschoor VL, Ploegh HL*. Front Immunol. 2021 Nov 3;12:777739. doi: 10.3389/fimmu.2021.777739.

24. Engineered red blood cells carrying PCSK9 inhibitors persistently lower LDL and prevent obesity.

Deshycka R, Sudaryo V, Huang NJ, Xie Y, Smeding LY, Choi MK, Ploegh HL, Lodish HF, Pishesha N*. PLoS One. 2021 Nov 3;16(11):e0259353. doi: 10.1371/journal.pone.0259353.

23. A class II MHC-targeted vaccine elicits immunity against SARS-CoV-2 and its variants.

Pishesha N*†, Harmand TJ †, Rothlauf PW †, Praest P, Alexander RK, van den Doel R, Liebeskind MJ, Vakaki MA, McCaul N, Wijne C, Verhaar E, Pinney W 3rd, Heston H, Bloyet LM, Pontelli MC, Ilagan MXG, Jan Lebbink R, Buchser WJ, Wiertz EJHJ, Whelan SPJ, Ploegh HL*. Proc Natl Acad Sci U S A. 2021 Nov 2;118(44):e2116147118. doi: 10.1073/pnas.2116147118.

22. Epithelial cells remove precancerous cells by cell competition via MHC class I-LILRB3 interaction.

Ayukawa S, Kamoshita N †, Nakayama J †, Teramoto R, Pishesha N, Ohba K, Sato N, Kozawa K, Abe H, Semba K, Goda N, Fujita Y, Maruyama T*. Nat Immunol. 2021 Nov;22(11):1391-1402. doi: 10.1038/s41590-021-01045-6.

21. Induction of antigen-specific tolerance by nanobody-antigen adducts that target class-II major histocompatibility complexes.

Pishesha N*, Harmand T †, Smeding LY †, Ma W, Ludwig LS, Janssen R, Islam A, Xie YJ, Fang T, McCaul N, Pinney W 3rd, Sugito HR, Rossotti MA, Gonzalez-Sapienza G, Ploegh HL*. Nat Biomed Eng. 2021 Nov;5(11):1389-1401. doi: 10.1038/s41551-021-00738-5.

20. Converting an Anti-Mouse CD4 Monoclonal Antibody into an scFv Positron Emission Tomography Imaging Agent for Longitudinal Monitoring of CD4+ T Cells.

Islam A, Pishesha N, Harmand TJ, Heston H, Woodham AW, Cheloha RW, Bousbaine D, Rashidian M, Ploegh HL*. J Immunol. 2021 Sep 1;207(5):1468-1477. doi: 10.4049/jimmunol.2100274.

19. An in vivo selection-derived d-peptide for engineering erythrocyte-binding antigens that promote immune tolerance.

Loftis AR †, Zhang G †, Backlund C, Quartararo AJ, Pishesha N, Hanna CC, Schissel CK, Garafola D, Loas A, Collier RJ, Ploegh H, Irvine DJ, Pentelute BL*. Proc Natl Acad Sci U S A. 2021 Aug 24;118(34):e2101596118. doi: 10.1073/pnas.2101596118.

18. Asparaginyl Ligase-Catalyzed One-Step Cell Surface Modification of Red Blood Cells.

Harmand TJ †, Pishesha N †, Rehm FBH, Ma W, Pinney WB, Xie YJ, Ploegh. HL* ACS Chem Biol. 2021 Jul 16;16(7):1201-1207. doi: 10.1021/acschembio.1c00216.

17. Notch4 signaling limits regulatory T-cell-mediated tissue repair and promotes severe lung inflammation in viral infections.

Harb H †, Benamar M †, Lai PS †, Contini P, Griffith JW, Crestani E, Schmitz-Abe K, Chen Q, Fong J, Marri L, Filaci G, Del Zotto G, Pishesha N, Kolifrath S, Broggi A, Ghosh S, Gelmez MY, Oktelik FB, Cetin EA, Kiykim A, Kose M, Wang Z, Cui Y, Yu XG, Li JZ, Berra L, Stephen-Victor E, Charbonnier LM, Zanoni I, Ploegh H, Deniz G, De Palma R ‡, Chatila TA*‡. Immunity. 2021 Jun 8;54(6):1186-1199.e7. doi: 10.1016/j.immuni.2021.04.002.

16. Nanobodies as in vivo, non-invasive, imaging agents.

Harmand TJ, Islam A, Pishesha N, Ploegh HL*. RSC Chem Biol. 2021 Mar 8;2(3):685-701. doi: 10.1039/d1cb00023c.

15. Improved Antitumor Efficacy of Chimeric Antigen Receptor T Cells that Secrete Single-Domain Antibody Fragments.

Xie YJ, Dougan M, Ingram JR, Pishesha N, Fang T, Momin N, Ploegh HL*. Cancer Immunol Res. 2020 Apr;8(4):518-529. doi: 10.1158/2326-6066.

14. Nanobody-based CAR T cells that target the tumor microenvironment inhibit the growth of solid tumors in immunocompetent mice.

Xie YJ, Dougan M, Jailkhani N, Ingram J, Fang T, Kummer L, Momin N, Pishesha N, Rickelt S, Hynes RO, Ploegh H*. Proc Natl Acad Sci U S A. 2019 Apr 16;116(16):7624-7631. doi: 10.1073/pnas.1817147116.

13. Improving hematopoietic recovery through modeling and modulation of the mesenchymal stromal cell secretome.

Liu FD, Tam K, Pishesha N, Poon Z, Van Vliet KJ*. Stem Cell Res Ther. 2018 Oct 24;9(1):268. doi: 10.1186/s13287-018-0982-2.

12. Sortase A: A Model for Transpeptidation and Its Biological Applications.

Pishesha N, Ingram JR, Ploegh HL*. Annu Rev Cell Dev Biol. 2018 Oct 6;34:163-188. doi: 10.1146/annurev-cellbio-100617-062527.

11. Enhanced phosphocholine metabolism is essential for terminal erythropoiesis.

Huang NJ, Lin YC, Lin CY, Pishesha N, Lewis CA, Freinkman E, Farquharson C, Millán JL, Lodish H*. Blood. 2018 Jun 28;131(26):2955-2966. doi: 10.1182/blood-2018-03-838516.

10. Targeting Cytokine Therapy to the Pancreatic Tumor Microenvironment Using PD-L1-Specific VHHs.

Dougan M †, Ingram JR †, Jeong HJ, Mosaheb MM, Bruck PT, Ali L, Pishesha N, Blomberg O, Tyler PM, Servos MM, Rashidian M, Nguyen QD, von Andrian UH, Ploegh HL, Dougan SK*. Cancer Immunol Res. 2018 Apr;6(4):389-401. doi: 10.1158/2326-6066.

9. Material Viscoelastic Properties Modulate the Mesenchymal Stem Cell Secretome for Applications in Hematopoietic Recovery.

Liu FD, Pishesha N, Poon Z, Kaushik T, Van Vliet KJ*. Material. ACS Biomater Sci Eng. 2017 Dec 11;3(12):3292-3306. doi: 10.1021/acsbiomaterials.7b00644

8. Localized CD47 blockade enhances immunotherapy for murine melanoma.

Ingram JR, Blomberg OS, Sockolosky JT, Ali L, Schmidt FI, Pishesha N, Espinosa C, Dougan SK, Garcia KC, Ploegh HL*, Dougan M*. Proc Natl Acad Sci U S A. 2017 Sep 19;114(38):10184-10189. doi: 10.1073/pnas.1710776114.

7. Genetically engineered red cells expressing single domain camelid antibodies confer long-term protection against botulinum neurotoxin.

Huang NJ †, Pishesha N †, Mukherjee J, Zhang S, Deshycka R, Sudaryo V, Dong M, Shoemaker CB*, Lodish HF*. Nat Commun. 2017 Sep 4;8(1):423. doi: 10.1038/s41467-017-00448-0.

6. Site-Specific Protein Labeling via Sortase-Mediated Transpeptidation.

Antos JM, Ingram J, Fang T, Pishesha N, Truttmann MC, Ploegh HL*. Curr Protoc Protein Sci. 2017 Aug 1;89:15.3.1-15.3.19. doi: 10.1002/cpps.38.

5. Engineered erythrocytes covalently linked to antigenic peptides can protect against autoimmune disease.

Pishesha N, Bilate AM, Wibowo MC, Huang NJ, Li Z, Deshycka R, Bousbaine D, Li H, Patterson HC, Dougan SK, Maruyama T, Lodish HF*, Ploegh HL*. Proc Natl Acad Sci U S A. 2017 Mar 21;114(12):3157-3162. doi: 10.1073/pnas.1701746114.

4. Efficient CRISPR-Cas9 mediated gene disruption in primary erythroid progenitor cells.

Li H †, Shi J †, Huang NJ, Pishesha N, Natarajan A, Eng JC, Lodish HF*. Haematologica. 2016 Jun;101(6):e216-9. doi: 10.3324/haematol.2015.135723.

3. Engineered red blood cells as carriers for systemic delivery of a wide array of functional probes.

Shi J †, Kundrat L †, Pishesha N, Bilate A, Theile C, Maruyama T, Dougan SK, Ploegh HL*, Lodish HF*. Proc Natl Acad Sci U S A. 2014 Jul 15;111(28):10131-6. doi: 10.1073/pnas.1409861111.

2. Transcriptional divergence and conservation of human and mouse erythropoiesis.

Pishesha N, Thiru P, Shi J, Eng JC, Sankaran VG*, Lodish HF*. Proc Natl Acad Sci U S A. 2014 Mar 18;111(11):4103-8. doi: 10.1073/pnas.1401598111.

1. Age dependent increase in the levels of osteopontin inhibits skeletal muscle regeneration.

Paliwal P*, Pishesha N, Wijaya D, Conboy IM*. Aging (Albany NY). 2012 Aug;4(8):553-66. doi: 10.18632/aging.100477.